TAFINLAR, also known by its generic name dabrafenib, is a prescription medication used in the treatment of certain types of cancers. Specifically, it is indicated for use in patients with melanoma that cannot be removed by surgery or has metastasized, and for non-small cell lung cancer (NSCLC) that exhibits a specific genetic mutation. TAFINLAR belongs to a class of drugs known as BRAF inhibitors, which work by targeting and inhibiting a specific protein (BRAF) that helps cancer cells grow. It is often used in combination with another medication, trametinib, to enhance its effectiveness. As with any cancer therapy, the use of TAFINLAR requires careful consideration and monitoring by a healthcare professional to manage its benefits against potential side effects.